

Mexico City, March 23, 2018

## GENOMMA LAB INTERNACIONAL INFORMS ABOUT COMPANIES NON-DILUTIVE MERGER

*Genomma Lab Internacional, S.A.B. de C.V.* (BMV: LAB B) (“Genomma Lab” or “the Company”), a Mexican company focused on the pharmaceutical and personal care products industry with presence in 19 countries, informs that in the past days, the conditions stated in the General Extraordinary Shareholders Meeting of the Company, held on April 27, 2017, have been fulfilled, so that the merger of the Company as surviving entity, with Hathaway South America Ventures, S.A. de C.V. and Saint Andrews Accelerated Growth Partners, S.A. de C.V., can take full effect. The only assets of the merged companies were shares representing the capital stock of certain South American subsidiaries of the Company.

As a result of the above, the Company does not have minority shareholders or partners in any of its subsidiaries.

### About the Company

---

*Genomma Lab Internacional, S.A.B. de C.V.* is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model. For more information visit: [www.genommalab.com](http://www.genommalab.com)

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.